

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

SUN PHARMACEUTICAL INDUSTRIES LTD. and  
SUN PHARMACEUTICAL INDUSTRIES, INC.,  
Petitioner,

v.

NOVO NORDISK A/S,  
Patent Owner.

---

IPR2024-00107  
Patent 10,335,462 B2

---

Before JOHN G. NEW, SUSAN L. C. MITCHELL, and  
ROBERT A. POLLOCK, *Administrative Patent Judges*.

MITCHELL, *Administrative Patent Judge*.

DECISION

Granting Institution of *Inter Partes* Review  
*35 U.S.C. § 314*

Granting Motion for Joinder  
*35 U.S.C. § 315(c); 37 C.F.R. § 42.122*

## I. INTRODUCTION

### *A. Background*

Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Inc. (“Petitioner”) filed a Petition requesting an *inter partes* review of claims 1–10 of U.S. Patent No. 10,335,462 B2 (Ex. 1001, “the ’462 patent”). Paper 3 (“Pet.”). Petitioner also filed a Motion for Joinder with the Petition seeking joinder with *Mylan Pharmaceuticals Inc. v. Novo Nordisk A/S*, IPR2023-00724 (“Mylan IPR”), which we have previously instituted on the same challenged claims of the ’462 patent. Paper 2 (“Mot.”); *see* IPR2023-00724, Paper 10 (PTAB Oct. 4, 2024) (“Mylan Dec.”).

Patent Owner Novo Nordisk A/S (“Patent Owner”) did not file an opposition to Petitioner’s Motion for Joinder. *See* Paper 8 (Joint Stipulation Regarding Petitioners’ Motion for Joinder”), 1. Patent Owner, however, filed a Preliminary Response requesting that we exercise our discretion to deny the Petition under 35 U.S.C. § 314(a) in light of the parallel district court proceeding and Petitioner’s delay in filing this Petition requesting *inter partes* review. Paper 10, 1–2.

Petitioner filed an authorized Reply addressing whether discretionary denial is appropriate. Paper 11. Patent Owner filed an authorized Sur-Reply in response. Paper 12.

We further authorized Petitioner to file an updated *Sotera*<sup>1</sup> stipulation that it filed with the District Court in parallel litigation in which it agrees

---

<sup>1</sup> *See Sotera Wireless, Inc. v. Masimo Corp.*, IPR2020-01019, Paper 12 (PTAB Dec. 1, 2020) (precedential as to § II.A) (discussing the petitioner’s broad stipulation to limit invalidity grounds in district court).

that it is estopped to the same extent as the petitioner in the original case to which it seeks joinder. *See* Exhibit 1099 (*Sotera* Stipulation). We also authorized Patent Owner an additional brief to address discretionary denial in view of Petitioner’s *Sotera* stipulation, and authorized Petitioner a one-page response. *See* Exhibit 3001; Papers 14, 15, respectively.

We have authority to determine whether to institute an *inter partes* review under 35 U.S.C. § 314 and 37 C.F.R. § 42.4(a). To institute an *inter partes* review, we must determine that the information presented in the Petition shows “a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314(a).

For the reasons set forth below, we decline to exercise our discretion to deny the Petition under 35 U.S.C. § 314(a) because of Petitioner’s *Sotera* stipulation and the postponement of the district court’s trial date, and conclude that Petitioner has established a reasonable likelihood that it would prevail in showing the unpatentability of at least one of the challenged claims of the ’462 patent. Therefore, we institute an *inter partes* review for claims 1–10 of the ’462 patent on the same grounds instituted in the Mylan IPR, and we grant Petitioner’s Motion for Joinder.

### *B. Related Proceedings*

The parties identify the following consolidated litigation involving the ’462 patent to which Petitioner is a defendant: (1) *Novo Nordisk Inc. and Novo Nordisk A/S v. Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc.*, No. 1:22-cv-00296 (D. Del.) (transferred to MDL on August 5, 2022); (2) *In re Ozempic (Semaglutide) Patent*

*Litigation*, No. 22-md-3038-CFC (D. Del.) (“Delaware Litigation”); and (3) *Novo Nordisk Inc. and Novo Nordisk A/S v. Rio Biopharmaceuticals, Inc. et al.*, No. 1:22-cv-00294 (D. Del.). Pet 1–2; Paper 5, 1–2; Paper 7, 1. The parties also list the following litigations that involve the ’462 patent: (1) *Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc.*, No. 1:22-cv-00295 (D. Del.) (dismissed on March 28, 2022); (2) *Novo Nordisk Inc. v. Rio Biopharmaceuticals, Inc.*, No. 1:22-cv-00294 (D. Del.); (3) *Novo Nordisk A/S v. Sun Pharm. Indus. Ltd.*, No. 1:22-cv-00296 (D. Del.); (4) *Novo Nordisk Inc. v. Zydus Worldwide DMCC*, No. 1:22-cv-00297 (D. Del.); (5) *Novo Nordisk Inc. v. Mylan Pharms. Inc.*, No. 22-cv-01040-CFC (D. Del.); (6) *Novo Nordisk Inc. v. Dr. Reddy’s Labs. Ltd.*, No. 1:22-cv-00298 (D. Del.); and (7) *Novo Nordisk Inc. v. Alvogen, Inc.*, No. 1:22-cv-00299 (D. Del.). Pet. 2; Paper 5, 1–2; Paper 7, 2.

The parties also identify the following *inter partes* review proceedings as a related matter involving the ’462 patent: *Mylan Pharmaceuticals Inc. v. Novo Nordisk A/S*, IPR2023-00724 (PTAB) and *Dr. Reddy’s Laboratories, Inc. and Dr. Reddy’s Labs., Ltd v. Novo Nordisk A/S*, IPR2024-00009, both of which are instituted. Pet. 2; Paper 5, 1; Paper 7, 3; *see* IPR2023-00724, Paper 10; IPR2024-00009, Paper 19. There is also one additional petition filed along with a motion for joinder to IPR2023-00724 that is pending decision on whether to institute trial: *Apotex Inc. v. Novo Nordisk A/S*, IPR2024-00631 (PTAB).

*C. Asserted Grounds of Unpatentability*

Petitioner asserts the following grounds of unpatentability, which are identical to the grounds on which we instituted trial in IPR2023-00724:

<b>Claim(s) Challenged</b>	<b>35 U.S.C. §<sup>2</sup></b>	<b>Reference(s)/Basis</b>
1–3	102(a), (e)	WO421 <sup>3</sup>
1–3	102(b)	Lovshin <sup>4</sup>
1–10	103(a)	WO421, '424 publication <sup>5</sup>
1–10	103(a)	WO537, <sup>6</sup> Lovshin
1–10	103(a)	NCT657, <sup>7</sup> NCT773, <sup>8</sup> '424 publication

*Compare* Pet. 4, with Mylan Dec. 6–7, 40.

---

<sup>2</sup> The Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011) (“AIA”), included revisions to 35 U.S.C. §§ 102 and 103 that became effective on March 16, 2013, after the filing of the applications to which the '462 patent claims priority. Therefore, we apply the pre-AIA versions of Sections 102 and 103.

<sup>3</sup> Thomas Klein et al., WO 2011/138421 A1, published November 10, 2011 (Ex. 1011, “WO421”).

<sup>4</sup> Julie A. Lovshin and Daniel J. Drucker, *Incretin-based therapies for type 2 diabetes mellitus*, 5 NATURE REVIEWS/ENDOCRINOLOGY 262–269 (2009) (Ex. 1012, “Lovshin”).

<sup>5</sup> Tina B. Pedersen et al., US 2007/0010424 A1, published Jan. 11, 2007 (Ex. 1016, “'424 publication”).

<sup>6</sup> Jesper Lau et al., WO 2006/097537 A2, published Sept. 21, 2006 (Ex. 1015, “WO537”).

<sup>7</sup> ClinicalTrials.gov, Clinical Trial No. NCT00696657, *A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide*, <http://web.archive.org/web/20111020123620/https://clinicaltrials.gov/ct2/show/NCT00696657> (Ex. 1013, “NCT657”).

<sup>8</sup> ClinicalTrials.gov, Clinical Trial No. NCT00851773, *Safety, Tolerability, and Profile of Action of Drug in the Body of NN9536 in Healthy Male Japanese and Caucasian Subjects*, <https://web.archive.org/web/20090911011536/https://clinicaltrials.gov/ct2/show/NCT00851773> (Ex. 1014, “NCT773”).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.